H63D HFE genotype accelerates disease progression in animal models of amyotrophic lateral sclerosis

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 12, 2014, Pages 2413-2426

  Nandar, Wint ^a   Neely, Elizabeth B ^a   Simmons, Zachary ^a   Connor, James R ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

ALS; Gliosis; H63D HFE; Iron; Oxidative stress; SOD1(G93A)

Indexed keywords

CASPASE 3; FERRITIN; HEME OXYGENASE 1; TAR DNA BINDING PROTEIN; TRANSCRIPTION FACTOR NF E2; TRANSFERRIN RECEPTOR; APOFERRITIN; COPPER ZINC SUPEROXIDE DISMUTASE; DNA BINDING PROTEIN; HFE PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; IRON; MEMBRANE PROTEIN; PROTEIN TDP-43; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DISRUPTION; CELL FUNCTION; CYTOPLASM; DISEASE COURSE; FEMALE; GENE; GENOTYPE; GLIOSIS; H67D HFE GENE; HOMEOSTASIS; IMMUNOREACTIVITY; LUMBAR SPINAL CORD; MALE; MICROGLIA; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; TRANSGENIC MOUSE; ANIMAL; DISEASE MODEL; FLUORESCENCE MICROSCOPY; GENETICS; HUMAN; INBRED MOUSE STRAIN; METABOLISM; MISSENSE MUTATION; MOTONEURON; MOTOR ACTIVITY; PATHOLOGY; PATHOPHYSIOLOGY; SURVIVAL; WESTERN BLOTTING;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; APOFERRITINS; BLOTTING, WESTERN; CASPASE 3; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DNA-BINDING PROTEINS; FEMALE; GENOTYPE; GLIOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IRON; MALE; MEMBRANE PROTEINS; MICE, INBRED STRAINS; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; MOTOR ACTIVITY; MOTOR NEURONS; MUTATION, MISSENSE; OXIDATIVE STRESS; SUPEROXIDE DISMUTASE; SURVIVAL ANALYSIS;

EID: 84910097448     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.09.016     Document Type: Article

References (75)

1. Ferraiuolo L., Kirby J., Grierson A.J., Sendtner M., Shaw P.J. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2011, 7:616-630.
2. Robberecht W., Philips T. The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 2013, 14:248-264.
3. Regal L., Vanopdenbosch L., Tilkin P., Van den Bosch L., Thijs V., Sciot R., Robberecht W. The G93C mutation in superoxide dismutase 1: clinicopathologic phenotype and prognosis. Arch. Neurol. 2006, 63:262-267.
4. Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J.P., Deng H.X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59-62.
5. Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., McCluskey L.F., Miller B.L., Masliah E., Mackenzie I.R., Feldman H., Feiden W., Kretzschmar H.A., Trojanowski J.Q., Lee V.M. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314:130-133.
6. Kwiatkowski T.J., Bosco D.A., Leclerc A.L., Tamrazian E., Vanderburg C.R., Russ C., Davis A., Gilchrist J., Kasarskis E.J., Munsat T., Valdmanis P., Rouleau G.A., Hosler B.A., Cortelli P., de Jong P.J., Yoshinaga Y., Haines J.L., Pericak-Vance M.A., Yan J., Ticozzi N., Siddique T., McKenna-Yasek D., Sapp P.C., Horvitz H.R., Landers J.E., Brown R.H. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009, 323:1205-1208.
7. DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J., Kouri N., Wojtas A., Sengdy P., Hsiung G.Y., Karydas A., Seeley W.W., Josephs K.A., Coppola G., Geschwind D.H., Wszolek Z.K., Feldman H., Knopman D.S., Petersen R.C., Miller B.L., Dickson D.W., Boylan K.B., Graff-Radford N.R., Rademakers R. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011, 72:245-256.
8. Oshiro S., Morioka M.S., Kikuchi M. Dysregulation of iron metabolism in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Adv. Pharmacol. Sci. 2011, 2011:378278.
9. Oba H., Araki T., Ohtomo K., Monzawa S., Uchiyama G., Koizumi K., Nogata Y., Kachi K., Shiozawa Z., Kobayashi M. Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. Radiology 1993, 189:843-846.
10. Kasarskis E.J., Tandon L., Lovell M.A., Ehmann W.D. Aluminum, calcium, and iron in the spinal cord of patients with sporadic amyotrophic lateral sclerosis using laser microprobe mass spectroscopy: a preliminary study. J. Neurol. Sci. 1995, 130:203-208.
11. Goodall E.F., Haque M.S., Morrison K.E. Increased serum ferritin levels in amyotrophic lateral sclerosis (ALS) patients. J. Neurol. 2008, 255:1652-1656.
12. Qureshi M., Brown R.H., Rogers J.T., Cudkowicz M.E. Serum ferritin and metal levels as risk factors for amyotrophic lateral sclerosis. Open Neurol. J. 2008, 2:51-54.
13. Nadjar Y., Gordon P., Corcia P., Bensimon G., Pieroni L., Meininger V., Salachas F. Elevated serum ferritin is associated with reduced survival in amyotrophic lateral sclerosis. PLoS One 2012, 7:e45034.
14. Jeong S.Y., Rathore K.I., Schulz K., Ponka P., Arosio P., David S. Dysregulation of iron homeostasis in the CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis. J. Neurosci. 2009, 29:610-619.
15. Wang Q., Zhang X., Chen S., Zhang S., Youdium M., Le W. Prevention of motor neuron degeneration by novel iron chelators in SOD1(G93A) transgenic mice of amyotrophic lateral sclerosis. Neurodegener. Dis. 2011, 8:310-321.
16. Merryweather-Clarke A.T., Pointon J.J., Shearman J.D., Robson K.J. Global prevalence of putative haemochromatosis mutations. J. Med. Genet. 1997, 34:275-278.
17. Nandar W., Connor J.R. HFE gene variants affect iron in the brain. J. Nutr. 2011, 141:729S-739S.
18. Wang X.S., Lee S., Simmons Z., Boyer P., Scott K., Liu W., Connor J. Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences. J. Neurol. Sci. 2004, 227:27-33.
19. Goodall E.F., Greenway M.J., van Marion I., Carroll C.B., Hardiman O., Morrison K.E. Association of the H63D polymorphism in the hemochromatosis gene with sporadic ALS. Neurology 2005, 65:934-937.
20. Restagno G., Lombardo F., Ghiglione P., Calvo A., Cocco E., Sbaiz L., Mutani R., Chio A. HFE H63D polymorphism is increased in patients with amyotrophic lateral sclerosis of Italian origin. J. Neurol. Neurosurg. Psychiatry 2007, 78:327.
21. Sutedja N.A., Sinke R.J., Van Vught P.W., Van der Linden M.W., Wokke J.H., Van Duijn C.M., Njajou O.T., Van der Schouw Y.T., Veldink J.H., Van den Berg L.H. The association between H63D mutations in HFE and amyotrophic lateral sclerosis in a Dutch population. Arch. Neurol. 2007, 64:63-67.
22. He X., Lu X., Hu J., Xi J., Zhou D., Shang H., Liu L., Zhou H., Yan B., Yu L., Hu F., Liu Z., He L., Yao X., Xu Y. H63D polymorphism in the hemochromatosis gene is associated with sporadic amyotrophic lateral sclerosis in China. Eur. J. Neurol. 2011, 18:359-361.
23. Yen A.A., Simpson E.P., Henkel J.S., Beers D.R., Appel S.H. HFE mutations are not strongly associated with sporadic ALS. Neurology 2004, 62:1611-1612.
24. Praline J., Blasco H., Vourc'h P., Rat V., Gendrot C., Camu W., Andres C.R. Study of the HFE gene common polymorphisms in French patients with sporadic amyotrophic lateral sclerosis. J. Neurol. Sci. 2012, 317:58-61.
25. van Rheenen W., Diekstra F.P., van Doormaal P.T., Seelen M., Kenna K., McLaughlin R., Shatunov A., Czell D., van Es M.A., van Vught P.W., van Damme P., Smith B.N., Waibel S., Schelhaas H.J., van der Kooi A.J., de Visser M., Weber M., Robberecht W., Hardiman O., Shaw P.J., Shaw C.E., Morrison K.E., Al-Chalabi A., Andersen P.M., Ludolph A.C., Veldink J.H., van den Berg L.H. H63D polymorphism in HFE is not associated with amyotrophic lateral sclerosis. Neurobiol. Aging 2013, 34:1517. (e1515-1517).
26. Ellervik C., Birgens H., Tybjaerg-Hansen A., Nordestgaard B.G. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls. Hepatology 2007, 46:1071-1080.
27. Nielsen J.E., Jensen L.N., Krabbe K. Hereditary haemochromatosis: a case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome. J. Neurol. Neurosurg. Psychiatry 1995, 59:318-321.
28. Berg D., Hoggenmuller U., Hofmann E., Fischer R., Kraus M., Scheurlen M., Becker G. The basal ganglia in haemochromatosis. Neuroradiology 2000, 42:9-13.
29. Bartzokis G., Lu P.H., Tishler T.A., Peters D.G., Kosenko A., Barrall K.A., Finn J.P., Villablanca P., Laub G., Altshuler L.L., Geschwind D.H., Mintz J., Neely E., Connor J.R. Prevalent iron metabolism gene variants associated with increased brain ferritin iron in healthy older men. J. Alzheimers Dis. 2010, 20:333-341.
30. Bartzokis G., Lu P.H., Tingus K., Peters D.G., Amar C.P., Tishler T.A., Finn J.P., Villablanca P., Altshuler L.L., Mintz J., Neely E., Connor J.R. Gender and iron genes may modify associations between brain iron and memory in healthy aging. Neuropsychopharmacology 2011, 36:1375-1384.
31. Nandar W., Neely E.B., Unger E., Connor J.R. A mutation in the HFE gene is associated with altered brain iron profiles and increased oxidative stress in mice. Biochim. Biophys. Acta 2013, 1832:729-741.
32. Ali-Rahmani F., Grigson P.S., Lee S., Neely E., Connor J.R., Schengrund C.L. H63D mutation in hemochromatosis alters cholesterol metabolism and induces memory impairment. Neurobiol. Aging 2014, 35:1511. (e1511-1512).
33. Lee S.Y., Patton S.M., Henderson R.J., Connor J.R. Consequences of expressing mutants of the hemochromatosis gene (HFE) into a human neuronal cell line lacking endogenous HFE. FASEB J. 2007, 21:564-576.
34. Mitchell R.M., Lee S.Y., Simmons Z., Connor J.R. HFE polymorphisms affect cellular glutamate regulation. Neurobiol. Aging 2011, 32:1114-1123.
35. Liu Y., Lee S.Y., Neely E., Nandar W., Moyo M., Simmons Z., Connor J.R. Mutant HFE H63D protein is associated with prolonged endoplasmic reticulum stress and increased neuronal vulnerability. J. Biol. Chem. 2011, 286:13161-13170.
36. Rothstein J.D. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol. 2009, 65(Suppl. 1):S3-S9.
37. Erikson K.M., Pinero D.J., Connor J.R., Beard J.L. Regional brain iron, ferritin and transferrin concentrations during iron deficiency and iron repletion in developing rats. J. Nutr. 1997, 127:2030-2038.
38. Drachman D.B., Frank K., Dykes-Hoberg M., Teismann P., Almer G., Przedborski S., Rothstein J.D. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann. Neurol. 2002, 52:771-778.
39. Arai T., Hasegawa M., Akiyama H., Ikeda K., Nonaka T., Mori H., Mann D., Tsuchiya K., Yoshida M., Hashizume Y., Oda T. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006, 351:602-611.
40. Mackenzie I.R., Bigio E.H., Ince P.G., Geser F., Neumann M., Cairns N.J., Kwong L.K., Forman M.S., Ravits J., Stewart H., Eisen A., McClusky L., Kretzschmar H.A., Monoranu C.M., Highley J.R., Kirby J., Siddique T., Shaw P.J., Lee V.M., Trojanowski J.Q. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann. Neurol. 2007, 61:427-434.
41. Robertson J., Sanelli T., Xiao S., Yang W., Horne P., Hammond R., Pioro E.P., Strong M.J. Lack of TDP-43 abnormalities in mutant SOD1 transgenic mice shows disparity with ALS. Neurosci. Lett. 2007, 420:128-132.
42. Tan C.F., Eguchi H., Tagawa A., Onodera O., Iwasaki T., Tsujino A., Nishizawa M., Kakita A., Takahashi H. TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol. 2007, 113:535-542.
43. Su X.W., Lee S.Y., Mitchell R.M., Stephens H.E., Simmons Z., Connor J.R. H63D HFE polymorphisms are associated with increased disease duration and decreased muscle superoxide dismutase-1 expression in amyotrophic lateral sclerosis patients. Muscle Nerve 2013, 48:242-246.
44. Heiman-Patterson T.D., Deitch J.S., Blankenhorn E.P., Erwin K.L., Perreault M.J., Alexander B.K., Byers N., Toman I., Alexander G.M. Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. J. Neurol. Sci. 2005, 236:1-7.
45. Heiman-Patterson T.D., Sher R.B., Blankenhorn E.A., Alexander G., Deitch J.S., Kunst C.B., Maragakis N., Cox G. Effect of genetic background on phenotype variability in transgenic mouse models of amyotrophic lateral sclerosis: a window of opportunity in the search for genetic modifiers. Amyotroph. Lateral Scler. 2011, 12:79-86.
46. Mancuso R., Olivan S., Mancera P., Pasten-Zamorano A., Manzano R., Casas C., Osta R., Navarro X. Effect of genetic background on onset and disease progression in the SOD1-G93A model of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2012, 13:302-310.
47. Moos T. Immunohistochemical localization of intraneuronal transferrin receptor immunoreactivity in the adult mouse central nervous system. J. Comp. Neurol. 1996, 375:675-692.
48. Dickinson T.K., Connor J.R. Immunohistochemical analysis of transferrin receptor: regional and cellular distribution in the hypotransferrinemic (hpx) mouse brain. Brain Res. 1998, 801:171-181.
49. Moos T., Oates P.S., Morgan E.H. Expression of the neuronal transferrin receptor is age dependent and susceptible to iron deficiency. J. Comp. Neurol. 1998, 398:420-430.
50. Zecca L., Youdim M.B., Riederer P., Connor J.R., Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 2004, 5:863-873.
51. Connor J.R., Boeshore K.L., Benkovic S.A., Menzies S.L. Isoforms of ferritin have a specific cellular distribution in the brain. J. Neurosci. Res. 1994, 37:461-465.
52. Rathore K.I., Redensek A., David S. Iron homeostasis in astrocytes and microglia is differentially regulated by TNF-alpha and TGF-beta1. Glia 2012, 60:738-750.
53. Appel S.H., Zhao W., Beers D.R., Henkel J.S. The microglial-motoneuron dialogue in ALS. Acta Myol. 2011, 30:4-8.
54. Mitchell R.M., Simmons Z., Beard J.L., Stephens H.E., Connor J.R. Plasma biomarkers associated with ALS and their relationship to iron homeostasis. Muscle Nerve 2010, 42:95-103.
55. Burguillos M.A., Deierborg T., Kavanagh E., Persson A., Hajji N., Garcia-Quintanilla A., Cano J., Brundin P., Englund E., Venero J.L., Joseph B. Caspase signalling controls microglia activation and neurotoxicity. Nature 2011, 472:319-324.
56. Boillee S., Yamanaka K., Lobsiger C.S., Copeland N.G., Jenkins N.A., Kassiotis G., Kollias G., Cleveland D.W. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006, 312:1389-1392.
57. Yamanaka K., Chun S.J., Boillee S., Fujimori-Tonou N., Yamashita H., Gutmann D.H., Takahashi R., Misawa H., Cleveland D.W. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat. Neurosci. 2008, 11:251-253.
58. Nagai M., Re D.B., Nagata T., Chalazonitis A., Jessell T.M., Wichterle H., Przedborski S. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat. Neurosci. 2007, 10:615-622.
59. Lee S.H., Kim J.W., Shin S.H., Kang K.P., Choi H.C., Choi S.H., Park K.U., Kim H.Y., Kang W., Jeong S.H. HFE gene mutations, serum ferritin level, transferrin saturation, and their clinical correlates in a Korean population. Dig. Dis. Sci. 2009, 54:879-886.
60. Petri S., Korner S., Kiaei M. Nrf2/ARE signaling pathway: key mediator in oxidative stress and potential therapeutic target in ALS. Neurol. Res. Int. 2012, 2012:878030.
61. Sarlette A., Krampfl K., Grothe C., Neuhoff N., Dengler R., Petri S. Nuclear erythroid 2-related factor 2-antioxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2008, 67:1055-1062.
62. Pehar M., Vargas M.R., Robinson K.M., Cassina P., Diaz-Amarilla P.J., Hagen T.M., Radi R., Barbeito L., Beckman J.S. Mitochondrial superoxide production and nuclear factor erythroid 2-related factor 2 activation in p75 neurotrophin receptor-induced motor neuron apoptosis. J. Neurosci. 2007, 27:7777-7785.
63. Neymotin A., Calingasan N.Y., Wille E., Naseri N., Petri S., Damiano M., Liby K.T., Risingsong R., Sporn M., Beal M.F., Kiaei M. Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radic. Biol. Med. 2011, 51:88-96.
64. Kensler T.W., Wakabayashi N., Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 2007, 47:89-116.
65. Vargas M.R., Johnson D.A., Johnson J.A. Decreased glutathione accelerates neurological deficit and mitochondrial pathology in familial ALS-linked hSOD1(G93A) mice model. Neurobiol. Dis. 2011, 43:543-551.
66. Sumi H., Kato S., Mochimaru Y., Fujimura H., Etoh M., Sakoda S. Nuclear TAR DNA binding protein 43 expression in spinal cord neurons correlates with the clinical course in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2009, 68:37-47.
67. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994, 264:1772-1775.
68. Julien J.P. A role for neurofilaments in the pathogenesis of amyotrophic lateral sclerosis. Biochem. Cell Biol. 1995, 73:593-597.
69. Figlewicz D.A., Krizus A., Martinoli M.G., Meininger V., Dib M., Rouleau G.A., Julien J.P. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum. Mol. Genet. 1994, 3:1757-1761.
70. Brettschneider J., Petzold A., Sussmuth S.D., Ludolph A.C., Tumani H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 2006, 66:852-856.
71. Reijn T.S., Abdo W.F., Schelhaas H.J., Verbeek M.M. CSF neurofilament protein analysis in the differential diagnosis of ALS. J. Neurol. 2009, 256:615-619.
72. Ganesalingam J., An J., Bowser R., Andersen P.M., Shaw C.E. pNfH is a promising biomarker for ALS. Amyotroph. Lateral Scler. Frontotemporal Degener. 2013, 14:146-149.
73. Boylan K., Yang C., Crook J., Overstreet K., Heckman M., Wang Y., Borchelt D., Shaw G. Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker. J. Neurochem. 2009, 111:1182-1191.
74. Rosengren L.E., Karlsson J.E., Karlsson J.O., Persson L.I., Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J. Neurochem. 1996, 67:2013-2018.
75. Zetterberg H., Jacobsson J., Rosengren L., Blennow K., Andersen P.M. Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur. J. Neurol. 2007, 14:1329-1333.